1. Home
  2. AXGN vs MESO Comparison

AXGN vs MESO Comparison

Compare AXGN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axogen Inc.

AXGN

Axogen Inc.

N/A

Current Price

$48.18

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

N/A

Current Price

$17.30

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AXGN
MESO
Founded
N/A
2004
Country
United States
Australia
Employees
N/A
108
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.2B
IPO Year
2013
2005

Fundamental Metrics

Financial Performance
Metric
AXGN
MESO
Price
$48.18
$17.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
1
Target Price
$42.33
N/A
AVG Volume (30 Days)
776.6K
179.9K
Earning Date
04-28-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$225,208,000.00
N/A
Revenue This Year
$20.57
$629.74
Revenue Next Year
$16.68
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
20.21
N/A
52 Week Low
$15.27
$13.05
52 Week High
$52.91
$21.50

Technical Indicators

Market Signals
Indicator
AXGN
MESO
Relative Strength Index (RSI) 49.18 53.65
Support Level $29.48 $16.56
Resistance Level $52.91 $17.33
Average True Range (ATR) 2.30 0.47
MACD -0.40 -0.04
Stochastic Oscillator 30.89 32.80

Price Performance

Historical Comparison
AXGN
MESO

About AXGN Axogen Inc.

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Share on Social Networks: